Literature DB >> 35933455

Molecular mechanism of Rhubarb in the treatment of non-small cell lung cancer based on network pharmacology and molecular docking technology.

Ye-Ru Tan1, Yu Lu2.   

Abstract

Non-small cell lung cancer (NSCLC) is one of the leading causes of death in the world. Rhubarb, a traditional Chinese medicine, has been widely used in the treatment of inflammatory and autoimmune diseases. This study aimed to investigate the possible mechanism of the rhubarb herb in the treatment of NSCLC by means of network pharmacology and molecular docking and to provide a theoretical basis for experiments and clinical application of traditional Chinese medicine for treating lung cancer. The main active chemical components and targets of rhubarb were screened through Swiss Target Prediction, TargetNet, and Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. The protein-protein interaction (PPI) network was built via an in-depth exploration of the relationships between the proteins. The enrichment analyses of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were applied to predict the potential roles in the pathogenesis of NSCLC via the R package cluster Profiler. Potential targets and active ingredients associated with anti-tumor effects of rhubarb were screened by reverse molecular docking. By searching databases and literature, a total of 295 targets were found for the 21 active ingredients in rhubarb. There were 68 common target genes associated with NSCLC, of which 9 are derived from FDA-approved drugs. GO Gene Set Enrichment Analysis (GSEA) explored up to 1103 biological processes, 62 molecular functions, and 18 cellular components. KEGG GSEA explored 65 basic pathways, and 71 disease pathways. Four key targets (JUN, EGFR, BCL2, and JAK2) were screened through the protein-protein interaction network, target-pathway network, and FDA drug-target network. Molecular docking results showed that these key targets had relatively strong binding activities with rhubarb's active ingredients. The present study explored the potential pharmacological mechanisms of rhubarb on NSCLC, promoting the clinical application of rhubarb in treating NSCLC, and providing references for advanced research.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Molecular docking; Network pharmacology; Non-small cell lung cancer; Rhubarb

Year:  2022        PMID: 35933455     DOI: 10.1007/s11030-022-10501-w

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   3.364


  43 in total

Review 1.  Ethnobotanical Uses, Phytochemistry and Pharmacology of Different Rheum Species (Polygonaceae): A Review.

Authors:  Leila Mohtashami; Mohammad Sadegh Amiri; Zahra Ayati; Mahin Ramezani; Tannaz Jamialahmadi; Seyed Ahmad Emami; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Effects of rhubarb extract on radiation induced lung toxicity via decreasing transforming growth factor-beta-1 and interleukin-6 in lung cancer patients treated with radiotherapy.

Authors:  Hui Ming Yu; Yun Fang Liu; Yu Feng Cheng; Li Kuan Hu; Ming Hou
Journal:  Lung Cancer       Date:  2007-09-17       Impact factor: 5.705

3.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

4.  Comparison of the Phytochemical Properties, Antioxidant Activity and Cytotoxic Effect on HepG2 Cells in Mongolian and Taiwanese Rhubarb Species.

Authors:  Ganbolor Jargalsaikhan; Jin-Yi Wu; Yen-Chou Chen; Ling-Ling Yang; Ming-Shun Wu
Journal:  Molecules       Date:  2021-02-25       Impact factor: 4.411

5.  Aloperine inhibits proliferation, migration and invasion and induces apoptosis by blocking the Ras signaling pathway in human breast cancer cells.

Authors:  Delong Tian; Yanhai Li; Xinxin Li; Zhenzhen Tian
Journal:  Mol Med Rep       Date:  2018-08-22       Impact factor: 2.952

6.  Emodin regulates neutrophil phenotypes to prevent hypercoagulation and lung carcinogenesis.

Authors:  Zibo Li; Yukun Lin; Shuhui Zhang; Lin Zhou; Guixi Yan; Yuehua Wang; Mengdi Zhang; Mengqi Wang; Haihong Lin; Qiaozhen Tong; Yongjian Duan; Gangjun Du
Journal:  J Transl Med       Date:  2019-03-18       Impact factor: 5.531

7.  Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.

Authors:  Shuifang Chen; Zeying Zhang; Jianli Zhang
Journal:  Drug Des Devel Ther       Date:  2019-04-10       Impact factor: 4.162

8.  Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively.

Authors:  Junjie Hu; Yan Chen; Xinsheng Zhu; Qiang Ma; Jing Zhang; Gening Jiang; Peng Zhang
Journal:  BMC Cancer       Date:  2021-04-22       Impact factor: 4.430

9.  Exploration in the mechanism of fucosterol for the treatment of non-small cell lung cancer based on network pharmacology and molecular docking.

Authors:  Xiaoling Li; Baixin Lin; Zhiping Lin; Yucui Ma; Qu Wang; Yushi Zheng; Liao Cui; Hui Luo; Lianxiang Luo
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

10.  Using Network Pharmacology and Molecular Docking to Explore the Mechanism of Shan Ci Gu (Cremastra appendiculata) Against Non-Small Cell Lung Cancer.

Authors:  Yan Wang; Yunwu Zhang; Yujia Wang; Xinyao Shu; Chaorui Lu; Shiliang Shao; Xingting Liu; Cheng Yang; Jingsong Luo; Quanyu Du
Journal:  Front Chem       Date:  2021-06-09       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.